Iqvia Holdings Inc (NYSE:IQV) insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $101.79, for a total transaction of $4,690,483.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ari Bousbib also recently made the following trade(s):

  • On Wednesday, November 1st, Ari Bousbib sold 46,080 shares of Iqvia stock. The shares were sold at an average price of $108.14, for a total transaction of $4,983,091.20.
  • On Monday, October 2nd, Ari Bousbib sold 46,080 shares of Iqvia stock. The shares were sold at an average price of $94.91, for a total transaction of $4,373,452.80.

Iqvia Holdings Inc (NYSE:IQV) opened at $101.01 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia Holdings Inc has a fifty-two week low of $74.73 and a fifty-two week high of $110.67. The company has a market cap of $21,316.11, a P/E ratio of 23.12, a PEG ratio of 1.66 and a beta of 0.61.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the prior year, the business posted $1.00 EPS. The business’s revenue for the quarter was up 77.6% compared to the same quarter last year. research analysts anticipate that Iqvia Holdings Inc will post 4.62 earnings per share for the current year.

IQV has been the topic of several recent analyst reports. BidaskClub lowered shares of Iqvia from a “strong-buy” rating to a “buy” rating in a report on Friday, August 11th. Argus boosted their target price on shares of Iqvia from $98.00 to $104.00 and gave the company a “buy” rating in a report on Monday, September 18th. Royal Bank Of Canada initiated coverage on shares of Iqvia in a report on Tuesday, September 19th. They issued an “outperform” rating and a $116.00 target price on the stock. KeyCorp reiterated a “buy” rating and issued a $100.00 target price on shares of Iqvia in a report on Sunday, September 24th. Finally, Robert W. Baird reiterated a “hold” rating and issued a $98.00 target price on shares of Iqvia in a report on Monday, October 9th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $105.23.

WARNING: “Ari Bousbib Sells 46,080 Shares of Iqvia Holdings Inc (IQV) Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/07/ari-bousbib-sells-46080-shares-of-iqvia-holdings-inc-iqv-stock.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.